Financials

News Ideas Discussions Technicals Forecast Seasonals Options

IMTX fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics. The company was founded on March 10, 2020, and is headquartered in Tuebingen, Germany.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

IMTX has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company